Iłecka J
Department of Neurology, Medical University, Lublin, Poland.
J Neural Transm (Vienna). 2004 Feb;111(2):167-72. doi: 10.1007/s00702-003-0086-7. Epub 2003 Dec 12.
The role of cyclic guanosine 5' monophosphate (cGMP) in neurodegeneration of motor neurons in amyotrophic lateral sclerosis (ALS) is still controversial. The aim of this study was to measure levels of cGMP in cerebrospinal fluid (CSF) of patients with ALS, and to investigate whether there is a relationship between CSF cGMP levels and clinical parameters of the disease. The study involved 30 ALS and 20 control group patients. The CSF cGMP was measured by the enzyme-linked immunosorbent assay. The results showed that levels of CSF cGMP were significantly decreased in the group of ALS patients compared to controls and did not depend on clinical state of ALS patients, type of ALS onset, or the duration of the disease. Decreased levels of CSF cGMP observed in this study may suggest the role of cGMP in neurodegeneration in ALS. The CSF cGMP cannot be a marker of the disease activity.
环磷酸鸟苷（cGMP）在肌萎缩侧索硬化症（ALS）运动神经元神经变性中的作用仍存在争议。本研究旨在测量ALS患者脑脊液（CSF）中cGMP的水平，并调查CSF中cGMP水平与该疾病临床参数之间是否存在关联。该研究纳入了30例ALS患者和20例对照组患者。采用酶联免疫吸附测定法测量CSF中的cGMP。结果显示，与对照组相比，ALS患者组的CSF cGMP水平显著降低，且不依赖于ALS患者的临床状态、ALS发病类型或疾病持续时间。本研究中观察到的CSF cGMP水平降低可能提示cGMP在ALS神经变性中的作用。CSF cGMP不能作为疾病活动的标志物。
